Palvella Therapeutics Operating Expenses 2014-2024 | PVLA

Palvella Therapeutics operating expenses from 2014 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Palvella Therapeutics Operating Expenses 2014-2024 | PVLA

Palvella Therapeutics operating expenses from 2014 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$141.5B
Gilead Sciences (GILD)$117.7B
Bristol Myers Squibb (BMY)$117.6B
Vertex Pharmaceuticals (VRTX)$105.8B
CSL (CSLLY)$85.8B
Regeneron Pharmaceuticals (REGN)$78.8B
GSK (GSK)$70.7B
Argenex SE (ARGX)$38.2B
Alnylam Pharmaceuticals (ALNY)$31.3B
BioNTech SE (BNTX)$27.3B
Biogen (BIIB)$21.8B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18B
Moderna (MRNA)$15.6B
Genmab (GMAB)$13.6B
Incyte (INCY)$13.4B
BioMarin Pharmaceutical (BMRN)$12.8B
Insmed (INSM)$12.6B
Sarepta Therapeutics (SRPT)$11.8B
Bio-Techne Corp (TECH)$11.6B
Vaxcyte (PCVX)$10.7B
Exact Sciences (EXAS)$10.6B
QIAGEN (QGEN)$10.3B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$9.1B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.5B
Repligen (RGEN)$8.2B